MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and Dementia

Phase 2positiveLiBBYPositive

AI Analysis

Summary

MediPharm Labs announced positive Phase II LiBBY trial results showing significant reduction in agitation in advanced dementia and Alzheimer's disease patients. Results were presented at AAIC in London on July 14, 2026.

Clinical Trial Data

Phase

Phase II

Primary Endpoint

Met

Outcome Details

Demonstrated significant reduction in agitation associated with advanced Alzheimer's disease and dementia

Importance:7/10

Sentiment:

0.80

Phase 2 dataAlzheimer's diseasedementiacannabinoidpositive resultsclinical trial

Related Companies

$MEDIF

Read the original article

Published by GlobeNewswire Pharma on July 14, 2026 12:35 PM

Read Original